Anti-galactocerebroside antibodies in human cerebrospinal fluids determined by enzyme-linked immunosorbent assay (ELISA).
The standard ELISA technique was improved for the detection of antigalactocerebroside antibody in biological fluid. Mouse monoclonal antigalactocerebroside antibody was used to demonstrate specificity and sensitivity of the technique. After optimization of the assay, the usefulness of this measurement for the evaluation of patients with multiple sclerosis was assessed. The presence of antigalactocerebroside antibodies in the cerebrospinal fluid of 20 patients with multiple sclerosis, 10 with other neurological diseases and 10 normal individuals was determined. All the CSF samples from normal individuals were negative. In patients with multiple sclerosis 14 of the 20 samples had elevated levels of antigalactocerebroside antibody, whereas with other neurological diseases 5 out of 10 were positive. Antigalactocerebroside levels were lower in samples from patients during an acute relapse than in those from more chronic cases. These results indicate that the presence of antigalactocerebroside antibody in cerebrospinal fluid is not specific to MS but may reflect previous damage to myelin.
D000911:Antibodies, Monoclonal; D001323:Autoantibodies / Q000134:cerebrospinal fluid*; D001927:Brain Diseases / Q000134:cerebrospinal fluid / Q000276:immunology*; D002554:Cerebrosides / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005699:Galactosylceramides / Q000276:immunology*; D007142:Immunoglobulin gamma-Chains / Q000134:cerebrospinal fluid; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid / Q000276:immunology*
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D002554:Cerebrosides; D005699:Galactosylceramides; D007142:Immunoglobulin gamma-Chains